Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for nebulized beta adrenergic agonist therapy for lung diseases, effective May 15, 2026. Here's what billing teams need to do.
CMS nebulized beta adrenergic agonist therapy has been a coverage flashpoint for years — and this modification keeps it squarely in that territory. The Centers for Medicare & Medicaid Services updated this policy in a space where medical necessity disputes and claim denial rates run high. The specific codes affected are not listed in the published policy document, which we'll address directly below. If your practice bills for nebulizer therapy in any respiratory context, this change deserves your attention before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Nebulized Beta Adrenergic Agonist Therapy for Lung Diseases |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Pulmonology, Internal Medicine, Family Medicine, DME Suppliers, Home Health |
| Key Action | Audit your nebulizer therapy billing protocols and medical necessity documentation before May 15, 2026 |
CMS Nebulized Beta Adrenergic Agonist Therapy Coverage Criteria and Medical Necessity Requirements 2026
CMS nebulized beta adrenergic agonist therapy coverage policy has always centered on one question: is the nebulizer form medically necessary, or can the patient use a metered-dose inhaler instead? That distinction hasn't gone away with this modification. It's the foundation of how Medicare thinks about reimbursement for this therapy, and it's the first thing a reviewer will look for in your documentation.
CMS requires documented medical necessity showing the patient cannot effectively use a metered-dose inhaler. That means your chart needs explicit clinical rationale — not a checkbox, not a boilerplate statement. If your physicians are writing "patient prefers nebulizer" without clinical support for why an MDI is contraindicated or ineffective, those claims are exposed.
The policy applies to patients with lung diseases including chronic obstructive pulmonary disease (COPD), asthma, and related lower respiratory conditions. Beta adrenergic agonists — think albuterol sulfate and similar agents — are the drug class in scope. These are among the most commonly billed respiratory therapies in Medicare, which is exactly why CMS reviews them closely and why this modification matters.
Prior authorization requirements under this policy depend on your Medicare Administrative Contractor. Some MACs require prior auth for home nebulizer setups; others don't. Check with your local MAC before assuming your current workflow is clean. If you're not certain how your MAC interprets this coverage policy, loop in your compliance officer before the May 15, 2026 effective date.
CMS Nebulized Beta Adrenergic Agonist Therapy Exclusions and Non-Covered Indications
CMS does not cover nebulized beta adrenergic agonist therapy when a patient can adequately use a pressurized metered-dose inhaler. That's the core exclusion, and it's been consistent across prior versions of this policy.
Nebulizer therapy billed without documented evidence that a MDI is clinically inappropriate will not meet medical necessity. CMS reviewers look for physician documentation of the patient's inability to coordinate inhaler use, severity of disease, or other clinical factors that make MDI delivery inadequate. "Convenience" is not a covered indication.
Therapy administered in the inpatient hospital setting is generally bundled — it does not get separately billed under this coverage framework. Your billing guidelines need to reflect that distinction clearly, especially if your team handles crossover cases between outpatient and inpatient settings.
Coverage Indications at a Glance
The published policy document does not list specific indication-by-code coverage status. The table below reflects the general coverage framework based on CMS's longstanding approach to this therapy. Confirm with your MAC and your compliance officer before treating this as exhaustive.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| COPD with documented inability to use MDI | Covered | Not specified in published policy | Requires physician documentation of MDI failure or contraindication |
| Asthma with documented inability to use MDI | Covered | Not specified in published policy | Same MDI necessity standard applies |
| Nebulizer therapy when MDI is clinically adequate | Not Covered | Not specified in published policy | Claim denial likely without documented MDI inadequacy |
| Inpatient hospital nebulizer therapy | Not Separately Covered | Not specified in published policy | Bundled under facility billing; do not bill separately |
| Patient preference for nebulizer without clinical basis | Not Covered | Not specified in published policy | Preference alone does not meet medical necessity |
CMS Nebulized Beta Adrenergic Agonist Therapy Billing Guidelines and Action Items 2026
This policy modification is effective May 15, 2026. That's your deadline. Here's what to do before then.
| # | Action Item |
|---|---|
| 1 | Audit your medical necessity documentation now. Pull a sample of recent nebulizer therapy claims. Check each one for documented clinical rationale explaining why an MDI is inadequate for that specific patient. If you're finding boilerplate language or missing documentation, fix your intake and order templates before May 15, 2026. |
| 2 | Confirm your MAC's prior authorization requirements. Medicare Administrative Contractor policies vary on nebulizer prior auth. Call or check your MAC's website to confirm whether prior authorization is required for home nebulizer setups in your region. Don't assume last year's workflow still applies. |
| 3 | Review your DME billing protocols for home nebulizer equipment. If your practice or an affiliated durable medical equipment supplier bills for home nebulizer equipment, the medical necessity standard in this policy applies to that equipment too. Align your DME billing documentation with the updated coverage policy criteria. |
| 4 | Train your clinical staff on the MDI-first standard. Physicians need to know that a nebulizer order without clinical justification for MDI failure is a billing liability. This isn't punitive — it's how the coverage policy works. A short internal training session before the effective date is worth the time. |
| 5 | Flag any pending claims billed before May 15, 2026. If you have claims in the pipeline for nebulizer therapy, check whether they meet the new documentation standards under the modified policy. Claims that don't meet medical necessity criteria under the updated policy are claim denial candidates during post-payment review. |
| 6 | Check your ICD-10 coding against documentation. Diagnosis codes for COPD, asthma, and related conditions need to match the clinical picture in the chart. If your billing team is coding J44.1 or J45.xx without corresponding documentation of severity and MDI inadequacy, that's a mismatch that auditors notice. (Note: the policy document does not list specific ICD-10 codes — work with your coders to confirm appropriate diagnosis coding for your patient population.) |
| 7 | Talk to your compliance officer if you have high nebulizer therapy volume. If nebulizer billing represents a significant share of your Medicare revenue, this modification warrants a formal internal review. Your compliance officer should assess your claim exposure under the updated coverage policy before May 15, 2026 — not after. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Nebulized Beta Adrenergic Agonist Therapy Under This CMS Policy
The published CMS policy document for this modification does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. We do not invent codes. Billing codes that appear in competitor summaries or older versions of this policy may not reflect the current modification.
Here's what that means for your team: you need to source your code list from the official policy document directly. Access the full policy at the source URL: https://app.payerpolicy.org/p/cms/321-v1.
Based on the general scope of nebulized beta adrenergic agonist therapy for lung diseases, the following code categories are typically relevant — but confirm against the actual policy text before updating your charge capture:
- HCPCS codes for nebulizer equipment (durable medical equipment codes, typically in the E-code series) and drug administration
- HCPCS drug codes for albuterol sulfate and other beta adrenergic agonist solutions (typically in the J-code series)
- ICD-10-CM codes for COPD and asthma with applicable severity and acuity specificity
Do not code from memory or from a peer's summary. Pull the actual policy, confirm the specific HCPCS and ICD-10 codes with your MAC's local coverage determination if one applies, and update your charge capture accordingly.
If your MAC has issued an LCD governing nebulized beta adrenergic agonist therapy in your region, that LCD takes precedence for your claims — and it will contain the specific code lists you need. Search the CMS LCD database for your MAC and cross-reference the LCD against this national policy modification.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.